JULIA ELIZABETH MCGUINNESS M.D.
Prescription History 1003201435
Internal Medicine - Medical Oncology in New York, NY


Quality Rating: 100 out of 100 score

NPI Status: Active since April 02, 2015

Contact Information

161 FORT WASHINGTON AVE FL 9
NEW YORK, NY
ZIP 10032
Phone: (212) 305-1945
Fax: (212) 305-0178

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JULIA ELIZABETH MCGUINNESS M.D., an active Medical Oncology specialist practicing in New York, NY. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 276 documented patient claims. Among these therapy options, the most frequently utilized medication is Anastrozole, which accounts for 130 claims alone.

Medication Index


Alendronate Sodium

Generic Formulation: Alendronate SodiumSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 19.4
Days Supply 568
NY State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills94.5
Peer Average Days Supply2,781
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.4% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $170.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.17

State Avg Cost Per Claim

$10.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Therapeutic Applications

Alendronate is used to prevent and treat certain types of bone loss (osteoporosis) in adults. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases as you age, after menopause, or if you are taking corticosteroid medications (such as prednisone) for a long time. This medication works by slowing bone loss. This effect helps maintain strong bones and reduce the risk of broken bones (fractures). Alendronate belongs to a class of drugs called bisphosphonates.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 130
30-Day Fills 206.0
Days Supply 6,180
NY State Average Benchmarks
Peer Average Claims64.0
Peer Average 30-Day Fills142.7
Peer Average Days Supply4,244
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 103.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,366.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.20

State Avg Cost Per Claim

$28.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 46
30-Day Fills 56.0
Days Supply 1,680
NY State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills65.1
Peer Average Days Supply1,939
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.8% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,786.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$125.79

State Avg Cost Per Claim

$280.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 29.0
Days Supply 870
NY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills106.0
Peer Average Days Supply3,158
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $334.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.66

State Avg Cost Per Claim

$29.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Prochlorperazine Maleate

Generic Formulation: Prochlorperazine MaleateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 124
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills27.0
Peer Average Days Supply376
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $203.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.50

State Avg Cost Per Claim

$19.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Therapeutic Applications

This medication is used to treat severe nausea and vomiting from certain causes (for example, after surgery or cancer treatment). Prochlorperazine belongs to a class of drugs known as phenothiazines. This medication is not recommended for use in children younger than 2 years or in children going through surgery.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 44.0
Days Supply 1,320
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills65.1
Peer Average Days Supply1,932
Conservative Utilization

This provider writes prescriptions for this formulation 25.8% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $612.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$26.63

State Avg Cost Per Claim

$35.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Verzenio

Generic Formulation: AbemaciclibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 896
NY State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.1
Peer Average Days Supply543
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 60.0% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $521,376.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,293.01

State Avg Cost Per Claim

$13,839.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer. Abemaciclib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JULIA ELIZABETH MCGUINNESS M.D. provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.